PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-19.03%
Negative revenue growth while AVGO stands at 1.82%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-70.57%
Negative gross profit growth while AVGO is at 1.48%. Joel Greenblatt would examine cost competitiveness or demand decline.
-218.87%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-218.87%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-202.45%
Negative net income growth while AVGO stands at 13.45%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-203.33%
Negative EPS growth while AVGO is at 12.24%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-206.90%
Negative diluted EPS growth while AVGO is at 12.50%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.98%
Share count expansion well above AVGO's 1.24%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-3.09%
Reduced diluted shares while AVGO is at 0.80%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
736.35%
OCF growth above 1.5x AVGO's 274.63%. David Dodd would confirm a clear edge in underlying cash generation.
85.32%
FCF growth under 50% of AVGO's 562.86%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
544.50%
10Y revenue/share CAGR above 1.5x AVGO's 50.51%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
24.88%
5Y revenue/share CAGR under 50% of AVGO's 50.51%. Michael Burry would suspect a significant competitive gap or product weakness.
-17.12%
Negative 3Y CAGR while AVGO stands at 50.51%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
93.19%
10Y OCF/share CAGR under 50% of AVGO's 232.18%. Michael Burry would worry about a persistent underperformance in cash creation.
-35.81%
Negative 5Y OCF/share CAGR while AVGO is at 232.18%. Joel Greenblatt would question the firm’s operational model or cost structure.
-90.09%
Negative 3Y OCF/share CAGR while AVGO stands at 232.18%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-947.31%
Negative 10Y net income/share CAGR while AVGO is at 480.38%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-266.67%
Negative 5Y net income/share CAGR while AVGO is 480.38%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-177.98%
Negative 3Y CAGR while AVGO is 480.38%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
1713.37%
10Y equity/share CAGR above 1.5x AVGO's 106.38%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
91.55%
5Y equity/share CAGR at 75-90% of AVGO's 106.38%. Bill Ackman might push for an improved ROE or share repurchase strategy to keep up.
16.70%
Below 50% of AVGO's 106.38%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.25%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
11.87%
We show growth while AVGO is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-1.89%
Negative asset growth while AVGO invests at 10.45%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.44%
We have a declining book value while AVGO shows 7.61%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-1.51%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-3.42%
Our R&D shrinks while AVGO invests at 4.11%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
8.79%
SG&A growth well above AVGO's 10.00%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.